A phase II study of oral etoposide in elderly patients with small cell lung cancer.

Thorax
E F SmitP E Postmus

Abstract

Thirty five previously untreated patients with small cell lung cancer older than 70 years were treated with oral etoposide (800 mg/m2 over five consecutive days) every four weeks. Twenty two patients had extensive disease and 13 limited disease. The overall response rate was 71%. The median survival for patients with limited diseases was 16 (range 6-32) months and for patients with extensive disease nine (range 4-17) months. There was mild haematological toxicity and alopecia but no major toxicity. It is concluded that etoposide in this dose regimen is an effective and well tolerated treatment for elderly patients with small cell lung cancer.

References

Jan 1, 1979·Journal of the American Academy of Child Psychiatry·K D Pruett
Sep 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M L SlevinP F Wrigley
Jun 1, 1987·European Journal of Cancer & Clinical Oncology·D A MorganJ Fletcher
Mar 1, 1987·Cancer Treatment Reports·E PoplinJ Aisner
Jan 1, 1987·European Journal of Cancer & Clinical Oncology·R J OsborneC R Franks
Jun 27, 1986·JAMA : the Journal of the American Medical Association·J SametJ S Goodwin

❮ Previous
Next ❯

Citations

May 15, 1996·Cancer·E DajczmanH Kreisman
Mar 1, 1993·Seminars in Surgical Oncology·R E Wittes
Jan 1, 1994·Cancer Chemotherapy and Pharmacology·S P Joel, M L Slevin
Jan 1, 1994·Cancer Chemotherapy and Pharmacology·C P BelaniJ Aisner
Mar 1, 1995·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·E DajczmanH Frank
Dec 26, 2001·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·S LariveUNKNOWN Groupe Lyon-Saint Etienne d'Oncologie Thoracique
May 16, 2002·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Cesare GridelliFrancesco Perrone
Mar 28, 2003·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Martin WeinmannCarsten Bokemeyer
Nov 1, 1996·Seminars in Oncology Nursing·V R Martin, R L Comis
Feb 14, 2002·Critical Reviews in Oncology/hematology·C GridelliS Monfardini
Jun 1, 1996·Thorax·J S BrownA G Davison
Oct 24, 2000·Drugs & Aging·R J Stephens, D H Johnson
Jul 3, 2002·Drugs & Aging·Stuart Hinton, Alan Sandler
Aug 15, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A KorfelE Thiel
Feb 13, 2001·Critical Reviews in Oncology/hematology·F GrossiA Ardizzoni
Feb 23, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C DebruyneUNKNOWN EORTC Lung Cancer Group
Sep 29, 2001·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·W Schuette
Jan 1, 1999·Chest·E D Chan, C H Welsh
Jan 5, 2006·Journal of Drug Targeting·Patlolla Ram Reddy, Vobalaboina Venkateswarlu
Jul 12, 2014·Drug Delivery·Prabhjot KaurAmit K Goyal
Dec 23, 2004·Journal of Pharmaceutical Sciences·R R Patlolla, V Vobalaboina
May 16, 2007·Journal of Pharmaceutical Sciences·Lingling TianXing Tang
Dec 16, 2005·Clinical Lung Cancer·Jennifer GarstJeffrey Crawford
May 1, 1996·Cancer Treatment Reviews·S Joel
Jan 1, 1992·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·D TummarelloR Cellerino
Apr 20, 2004·Hematology/oncology Clinics of North America·Branislav JeremicMichael Molls
Oct 12, 2000·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·S SenguptaS K Gupta
Jun 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Harvey B NiellUNKNOWN Cancer and Leukemia Group
Jun 22, 2005·The Oncologist·Antonio RossiCesare Gridelli
Nov 28, 2013·The Cochrane Database of Systematic Reviews·Marta Pelayo AlvarezXavier Bonfill Cosp
Nov 30, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E FokkemaI E Smith

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
M P FindlayP Gianoutsos
© 2022 Meta ULC. All rights reserved